PDF(Sci-hub)
Abstract：
Endocrine treatment represents the cornerstone of endocrine-sensitive pre-menopausal early breast cancer. The estrogen blockade plays a leading role in the therapeutic management with surgery, radiotherapy and selective antiestrogen treatment. For several years, selective estrogen receptor modulators, such as tamoxifen, have revolutionized medical care of hormone receptors-positive breast cancer and have conquered the therapeutic arsenal while becoming the gold standard of treatment. Other combinations associating the ovarian function suppression using LHRH agonists with tamoxifen or aromatase inhibitors have been recently investigated, leading to mitigated opinions regarding the clinical benefit of these associations. We propose here a comprehensive overview on existing data and their actualization concerning LHRH analogues, whilst emphasizing benefit-risk balance for this targeted population.
摘要：
内分泌治疗是内分泌敏感的绝经前早期乳腺癌的基石。雌激素阻滞剂在手术治疗管理中起着主导作用，放疗和选择性抗雌激素治疗。几年来,选择性雌激素受体调节剂，如他莫昔芬，彻底改变了激素受体阳性乳腺癌的医疗保健，并征服了治疗武器库，同时成为治疗的黄金标准。最近研究了使用LHRH激动剂与他莫昔芬或芳香化酶抑制剂相关的其他组合，导致关于这些关联的临床益处的缓解意见。我们在这里提出了关于LHRH类似物的现有数据及其实现的全面概述，同时强调这一目标人群的利益-风险平衡。
